MedPath

XARACOLL

These highlights do not include all the information needed to use XARACOLL safely and effectively. See full prescribing information for XARACOLL. XARACOLL (bupivacaine hydrochloride) implantInitial U.S. Approval: 1972

Approved
Approval ID

46da5733-c892-43a5-b826-1898a753f1c3

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 8, 2020

Manufacturers
FDA

INNOCOLL PHARMACEUTICALS

DUNS: 989921395

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Bupivacaine HCl Collagen-matrix

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code51715-100
Application NumberNDA209511
Product Classification
M
Marketing Category
C73594
G
Generic Name
Bupivacaine HCl Collagen-matrix
Product Specifications
Route of AdministrationParenteral
Effective DateSeptember 9, 2020
FDA Product Classification

INGREDIENTS (1)

BUPIVACAINEActive
Quantity: 100 mg in 1 1
Code: Y8335394RO
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

XARACOLL - FDA Drug Approval Details